PharmaCyte Biotech Balance Sheet Health
Financial Health criteria checks 6/6
PharmaCyte Biotech has a total shareholder equity of $54.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $71.4M and $17.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$61.21m |
| Equity | US$54.18m |
| Total liabilities | US$17.18m |
| Total assets | US$71.36m |
Recent financial health updates
Recent updates
PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business
Mar 22
PharmaCyte Biotech says CEO to step down, announces strategic review of business
Oct 07PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors
Aug 15Is This A Good Time To Invest In PharmaCyte?
Jan 07PharmaCyte Biotech: Buy The 'Dump'
Aug 21Financial Position Analysis
Short Term Liabilities: PMCB's short term assets ($61.5M) exceed its short term liabilities ($2.2M).
Long Term Liabilities: PMCB's short term assets ($61.5M) exceed its long term liabilities ($14.9M).
Debt to Equity History and Analysis
Debt Level: PMCB is debt free.
Reducing Debt: PMCB had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PMCB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: PMCB has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 3.2% each year